Skip to content

To Evaluate The Anrogens and Ovary Function in In Vitro Fertilization

To Evaluate The Androgens and Ovary Function Impact on The Pregnancy Outcome in In Vitro Fertilization

Status
Suspended
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01600794
Enrollment
1000
Registered
2012-05-17
Start date
2011-10-31
Completion date
2012-10-31
Last updated
2012-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

In Vitro Fertilization

Keywords

In Vitro Fertilization (IVF), androgens, ovary function, This study include the patients who are evaluated by the doctors and are sure to process the In Vitro Fertilization cycle.

Brief summary

Because the society convention is changed, people are late for getting married, leading to increasing the bearing age in women. According to the previous study, if the age is over 30, the oocyte number in ovary has left only 10% and 3% in over 40 years old. The data is collected by Bureau of Health Promotion, Department of Health shows that there are about 7000 people treating the infertility and it spends about 150000 to 250000 NT dollars in every in vitro fertilization (IVF) cycle, but the live birth rate is only 30%. So it is important to know how to estimate and approve the ovary function that lead to increase the live birth rate. The investigators plan to estimate the correlation between the serum androgens levels and pregnancy outcome in the women who have infertility problem. Furthermore, for the repeated IVF cycle, the ovary function might be re-evlauated because of the possible effect from stimulated drugs used on previous cycle. It's important to understand the ovary function for IVF patient to choose the appropriate drugs and dose. The investigators use blood and clinical test to analyze, the items for analysis are below: 1. Routine blood test: FSH、LH、E2、P4、Anti-Mullerian Hormone(AMH)、 2. Studied blood test: Inhibin B、total testosterone (TT)、Androstenedione、DHEA-S 3. Clinical test: Ultrasound 4. Personal condition. In order to finishing the test, every patient will be asked to collect about 10 to 15 cc blood for the research.

Interventions

None listed

Sponsors

Taipei Medical University WanFang Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* This study include the patients who are evaluated by the doctors and are sure to process the IVF cycle.

Exclusion criteria

* This study exclude the patients who are not evaluated by the doctors and are not sure to process the IVF cycle.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026